<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070953</url>
  </required_header>
  <id_info>
    <org_study_id>0653-175</org_study_id>
    <secondary_id>2010_009</secondary_id>
    <nct_id>NCT01070953</nct_id>
  </id_info>
  <brief_title>EZETROL® Re-examination Study (MK0653-175)(COMPLETED)</brief_title>
  <official_title>Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of EZETROL® in Usual Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This survey is conducted for preparing application materials for re-examination under the
      Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the
      clinical usefulness of EZETROL® through collecting the safety information according to the
      Re-examination Regulation for New Drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Any Clinical and/or Laboratory Adverse Experience While Being Treated With EZETROL® Within 14 Days After Treatment Discontinuation</measure>
    <time_frame>Up to 14 days after treatment discontinuation</time_frame>
    <description>Participants who recieved EZETROL® and experienced any adverse event related or unrelated to EZETROL®, within 14 days after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline to Treatment in Lipid Parameters</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>The mean percent change from baseline to treatment in lipid parameters (total cholesterol [TC], low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides[TG]) in participants who received EZETROL over 4 weeks and then had available laboratory results in Lipid Parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Efficacy Evaluation of EZETROL®</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Participants who received EZETROL over 4 weeks and then have been evaluated for overall efficacy assessment by investigator showing to be improved, unchanged or worsened.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4467</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>EZETROL® 10 mg</arm_group_label>
    <description>Participants with Hypercholesterolemia treated with EZETROL®</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Hypercholesterolemia treated with EZETROL®
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants Who Receives EZETROL® In Usual Medical Practice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <results_first_submitted>July 28, 2011</results_first_submitted>
  <results_first_submitted_qc>September 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2011</results_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EZETROL® 10 mg</title>
          <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia(HoFH) treated with EZETROL® 10 mg once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Participants for Safety Evaluation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4467"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3536"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="931"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Violation of inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="612"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Off-label use</title>
              <participants_list>
                <participants group_id="P1" count="283"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Duplicated participants</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment prior to date of contract</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Uncontracted participants</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of inclusions &amp; off label use</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Duplicated participants &amp; off-label use</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Participants for Efficacy Evaluation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3536"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3309"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No efficacy evaluation</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of treatment period (&lt;28 days)</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown date of efficacy evaluation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EZETROL® 10 mg</title>
          <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia(HoFH) treated with EZETROL® 10 mg once daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3536"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>age &lt; 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 ≤ age &lt; 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 ≤ age &lt; 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 ≤ age &lt; 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 ≤ age &lt; 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 ≤ age &lt; 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 ≤ age &lt; 80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 ≤ age &lt; 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>age ≥ 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Any Clinical and/or Laboratory Adverse Experience While Being Treated With EZETROL® Within 14 Days After Treatment Discontinuation</title>
        <description>Participants who recieved EZETROL® and experienced any adverse event related or unrelated to EZETROL®, within 14 days after treatment.</description>
        <time_frame>Up to 14 days after treatment discontinuation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EZETROL® 10 mg</title>
            <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia(HoFH) treated with EZETROL® 10 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Any Clinical and/or Laboratory Adverse Experience While Being Treated With EZETROL® Within 14 Days After Treatment Discontinuation</title>
          <description>Participants who recieved EZETROL® and experienced any adverse event related or unrelated to EZETROL®, within 14 days after treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline to Treatment in Lipid Parameters</title>
        <description>The mean percent change from baseline to treatment in lipid parameters (total cholesterol [TC], low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides[TG]) in participants who received EZETROL over 4 weeks and then had available laboratory results in Lipid Parameters.</description>
        <time_frame>Baseline to 4 weeks</time_frame>
        <population>3,309 subjects were analyzed for the efficacy
evaluation; 227 of the enrolled subjects did not complete the study and were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline to Treatment in Lipid Parameters</title>
          <description>The mean percent change from baseline to treatment in lipid parameters (total cholesterol [TC], low-density lipoprotein [LDL] cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides[TG]) in participants who received EZETROL over 4 weeks and then had available laboratory results in Lipid Parameters.</description>
          <population>3,309 subjects were analyzed for the efficacy
evaluation; 227 of the enrolled subjects did not complete the study and were excluded</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TC (n = 2439)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.23" spread="21.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL (n = 1928)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.47" spread="19.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL (n = 1774)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.06" spread="33.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG ( n = 2083)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.37" spread="45.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Efficacy Evaluation of EZETROL®</title>
        <description>Participants who received EZETROL over 4 weeks and then have been evaluated for overall efficacy assessment by investigator showing to be improved, unchanged or worsened.</description>
        <time_frame>Baseline to 4 weeks</time_frame>
        <population>3,309 subjects were analyzed for the efficacy evaluation; 227 of the enrolled subjects did not complete the study and were excluded</population>
        <group_list>
          <group group_id="O1">
            <title>EZETROL® 10 mg</title>
            <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia(HoFH) treated with EZETROL® 10 mg once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Efficacy Evaluation of EZETROL®</title>
          <description>Participants who received EZETROL over 4 weeks and then have been evaluated for overall efficacy assessment by investigator showing to be improved, unchanged or worsened.</description>
          <population>3,309 subjects were analyzed for the efficacy evaluation; 227 of the enrolled subjects did not complete the study and were excluded</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Year 1 through Year 6.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EZETROL Year 1</title>
          <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia(HoFH) treated with EZETROL® 10 mg once daily in Year 1.</description>
        </group>
        <group group_id="E2">
          <title>EZETROL Year 2</title>
          <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia(HoFH) treated with EZETROL® 10 mg once daily in Year 2.</description>
        </group>
        <group group_id="E3">
          <title>EZETROL Year 3</title>
          <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia(HoFH) treated with EZETROL® 10 mg once daily in Year 3.</description>
        </group>
        <group group_id="E4">
          <title>EZETROL Year 4</title>
          <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia(HoFH) treated with EZETROL® 10 mg once daily in Year 4.</description>
        </group>
        <group group_id="E5">
          <title>EZETROL Year 5</title>
          <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia(HoFH) treated with EZETROL® 10 mg once daily in Year 5.</description>
        </group>
        <group group_id="E6">
          <title>EZETROL Year 6</title>
          <description>Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia(HoFH) treated with EZETROL® 10 mg once daily in Year 6.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1135"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="1039"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>CARDIAC DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS NEUROSENSORY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>EXTRADURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>NEUROPATHIC ARTHROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>PARATHYROID TUMOUR BENIGN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>NEUROLEPTIC MALIGNANT SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>QUADRIPLEGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1039"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>VOCAL CORD POLYP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1135"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1135"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1039"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1135"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1039"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="766"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E6" events="29" subjects_affected="29" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

